Nussbaum Law Group, P.C. and Roberts Law Firm US, PC Announce a $73.5 Million Class Action Settlement with Mylan on Behalf of Direct Purchasers of EpiPen® or Generic EpiPen

NEW YORK--(BUSINESS WIRE)--Nussbaum Law Group, P.C. and Roberts Law Firm US, PC: COURT-ORDERED LEGAL NOTICE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF KANSAS   If you purchased EpiPen® or generic EpiPen directly from the manufacturer, you may receive a payment from a $73.5 million class action settlement. KPH Healthcare Services, Inc. v. Mylan N.V., Case No. 2:20-cv-02065-DDC-TJJ (District of Kansas)   This is not a recall, safety, or other similar notice. No one is claiming that EpiPen i.

Business Wire • Mar 13, 2025

US DOJ drops Viatris unit Mylan from industry-wide antitrust probe

Viatris said on Tuesday that its unit Mylan is no longer a subject of the U.S. Department of Justice's antitrust investigation into alleged price fixing in the generic drug industry.

Reuters • Jul 2, 2024

Scott+Scott Attorneys at Law LLP & Hedin Hall LLP Announce Notice of Class Action and Proposed Settlement to All Who Purchased or Acquired Shares of Viatris Inc. Pursuant to a November 2020 Merger of Mylan N.V. and Upjohn, Inc. to Form Viatris

NEW YORK , March 11, 2024 /PRNewswire/ -- IN THE COURT OF COMMON PLEAS OF ALLEGHENY COUNTY, PENNSYLVANIA RAJESH PATEL, Individually and on Behalf of All Others Similarly Situated,                                                   Plaintiff, v. VIATRIS, INC.

PRNewsWire • Mar 11, 2024

Former Mylan executive pleads guilty to insider trading

A former information technology executive at Mylan pleaded guilty on Friday to insider trading for using tips from the drugmaker's chief information officer to trade in its stock, generating $4.27 million of illegal profit, authorities said.

Reuters • Sep 17, 2021

Is Mylan (VTRS) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research • Jan 20, 2021

2 Best Pharma Stocks to Buy in November

The two pharma stocks offer investors the upside of a coronavirus vaccine with the peace of mind of century-old businesses.

The Motley Fool • Nov 10, 2020

Mylan (MYL) Q3 Earnings Surpass Estimates

Mylan (MYL) delivered earnings and revenue surprises of 14.78% and -0.24%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research • Nov 6, 2020

Mylan's (MYL) Q3 Earnings Surpass Estimates, Sales Miss

Mylan (MYL) beats on Q3 earnings but misses on sales. The company is all set to merge with Pfizer's Upjohn business later in the month.

Zacks Investment Research • Nov 6, 2020

3 Reasons Pfizer's Imminent Upjohn-Mylan Merger Is Great News for Investors

There really isn't a downside to this deal.

The Motley Fool • Nov 6, 2020

Why Mylan (MYL) Might Surprise This Earnings Season

Mylan (MYL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Investment Research • Nov 2, 2020